Related Experiment Video
Updated: Feb 3, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Abuse Potential of Biased Mu Opioid Receptor Agonists
S Stevens Negus1, Kevin B Freeman2
1Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Abstract:
G protein-biased mu opioid receptor (GPB-MOR) agonists constitute an emerging class of opioid analgesics. The first-in-class GPB-MOR agonist TRV130 (oliceridine) produces typical opioid-like abuse-related effects in rodents and humans. Although GPB-MOR agonists may be safer than conventional opioids on some endpoints, prevailing evidence suggests that they will retain opioid-like abuse potential.
Insights
G protein-biased mu opioid receptor (GPB-MOR) agonists, like oliceridine, show typical opioid-like abuse potential. Despite potential safety benefits, these emerging analgesics are expected to retain abuse risks.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Development
Background:
- G protein-biased mu opioid receptor (GPB-MOR) agonists represent a novel class of analgesics.
- Conventional opioids carry significant risks of abuse and addiction.
Purpose of the Study:
- To evaluate the abuse potential of GPB-MOR agonists.
- To understand the safety profile of emerging opioid analgesics.
Main Methods:
- Preclinical and clinical studies were conducted.
- Abuse-related effects were assessed in rodents and humans.
Main Results:
- The first-in-class GPB-MOR agonist, TRV130 (oliceridine), demonstrated typical opioid-like abuse-related effects.
- Evidence suggests these effects occur in both animal models and human subjects.
Conclusions:
- GPB-MOR agonists, while potentially safer on certain measures, are likely to retain abuse potential similar to conventional opioids.
- Further research is needed to fully characterize the risks associated with this emerging drug class.
More Related Videos
08:11Measuring Caenorhabditis elegans Sensitivity to the Acetylcholine Receptor Agonist Levamisole
Published on: June 7, 2022
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
Opioid Receptors: Overview
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Confirmation Biases
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists